Patient Search
 |
 |
|
KaCrole Higgins was diagnosed with breast cancer in 2020. “In May 2020, I found a lump in my breast. I cried. By June, it was diagnosed as breast cancer, triple positive, stage 1A. While getting this cancer diagnosis was devastating, it also became an opportunity. Suddenly, the cancer gave me clarity. It gave me clarity about what was important, what was good in my life, what was toxic in my life, and what I needed to do.” Click below to read more of KaCrole’s story |
If Landon Ryan had been diagnosed with bilateral retinoblastoma 10, 20 or 30 years ago, she might not be here today with nearly perfect vision.Thanks to recent improvements in the treatment for this rare form of cancer that almost exclusively affects children under the age of 5, the diagnosis had the power to change Landon’s life when she was 11 months old, but not to take it — or her eyesight. Click below to learn more about Landon and her story. https://momentum.vicc.org/2022/04/brighter-outlook/ |
A Multicenter, Randomized, Double-Blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Head/Neck
Head/Neck
Head/Neck
II/III
Choe, Jennifer
NCT06788990
VICC-DTHAN23428
An Interventional, Phase 3, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Pf-08634404 in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Treatment-Nave Participants with Metastatic Colorectal Cancer
Colon
Colon
Colon
III
Eng, Cathy
NCT07222800
VICCGI25060
Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)
Kidney (Renal Cell)
Kidney (Renal Cell)
Kidney (Renal Cell)
II
Rini, Brian
NCT05361720
VICCURO21103
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of LYL314, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants with Aggressive B-Cell Non-Hodgkin Lymphoma
Lymphoma
Lymphoma
Lymphoma
I/II
Dholaria, Bhagirathbhai
NCT05826535
VICCCTT25034
An Interventional, Open-Label, Randomized, Multicenter, Phase 3 study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-Based Therapy
Breast
Breast
Breast
III
Abramson, Vandana
NCT07062965
VICCBRE25026
A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma
Neuro-Oncology
Neuro-Oncology
Neuro-Oncology
II
Mohler, Alexander
NCT05425004
VICC-ITNEU23261
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Multiple Cancer Types
Colon,
Esophageal,
Gastric/Gastroesophageal,
Gastrointestinal,
Liver,
Pancreatic,
Rectal
N/A
Idrees, Kamran
NCT06016855
VICCGI2283
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects with Advanced KRAS Mutant Cancers
Multiple Cancer Types
Colon,
Lung,
Miscellaneous,
Pancreatic
I
Eng, Cathy
NCT06917079
VICCPHI25051
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
III
Sengsayadeth, Salyka
NCT03937635
ECOGPCLEAA173
A Phase I, Open Label Single-Arm Two-Part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subjects with Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and with Other Solid Tumors
Miscellaneous
Miscellaneous
Miscellaneous
I
Berlin, Jordan
NCT06326411
VICC-DTPHI23579
